https://www.socictopen.socict.org/files/original/dc1b9192b3b83e9761be3738cce5c32d.pdf 6fa1b8a2ef67d64cdc411162822f6dfb Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Coronavirus Description An account of the resource Dominio científico: Coronavirus Text A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text. Dublin Core The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/. Title A name given to the resource Impact of influenza vaccination on the risk of SARS-CoV-2 infection in a middle-aged group of people. Creator An entity primarily responsible for making the resource Andrzej Bozek, Renata Kozłowska, Beata Galuszka, Alicja Grzanka Description An account of the resource Aims: An observational study of a retrospective cohort was performed to assess the impact of influenza vaccination (IV) on the risk of SARS-CoV-2 infection in a population of middle-aged people for 8 weeks after IV and compared with an unvaccinated group.Patients and methods: Data from 1098 middle-aged patients (53.7 ± 4.7 years) after IV and 1205 unvaccinated patients (50.1 ± 6.8 years) were analyzed based on medical documentation. The inclusion criteria were age between 40 - 60 years and IV in the period from 1-30 September 2020. The incidence of infection with SARS-CoV-2 was confirmed by PCR and the classification of ICD-10 (U07.1).Results and conclusions: After IV, patients had significantly fewer SARS-CoV-2 infections than the unvaccinated patients (P = .017). The hazard ratio was 0.74 (95% CI: 0.54-0.89). IV may partially reduce the risk of SARS-CoV-2 infection. Date A point or period of time associated with an event in the lifecycle of the resource 2021 Subject The topic of the resource influenza, vaccine, SARS-CoV-2, Immunotherapy, Comparative effectiveness Identifier An unambiguous reference to the resource within a given context 10.1080/21645515.2021.1913961 Source A related resource from which the described resource is derived Human vaccines & immunotherapeutics